This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Veliparib (ABT888) Monotherapy for Patients with B...
Clinical trial

Veliparib (ABT888) Monotherapy for Patients with BRCA germline mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer

Read time: 1 mins
Last updated:29th Jul 2011
Phase I: To determine: � Maximum-tolerated dose (MTD) � Dose-limiting toxicities (DLT) � Recommended phase II dose Phase II: To investigate the response rate in platinum-resistant and partially platinum sensitive ovarian cancer patients with known BRCA mutations treated with veliparib monotherapy.
Category Value
Study start date 2011-07-29

View full details